Tacrolimus ointment 0.03% for treatment of refractory childhood phlyctenular keratoconjunctivitis.

Détails

ID Serval
serval:BIB_E0370F66D380
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Compte-rendu: analyse d'une oeuvre publiée.
Collection
Publications
Institution
Titre
Tacrolimus ointment 0.03% for treatment of refractory childhood phlyctenular keratoconjunctivitis.
Périodique
Cornea
Auteur(s)
Kymionis G.D., Kankariya V.P., Kontadakis G.A.
ISSN
1536-4798 (Electronic)
ISSN-L
0277-3740
Statut éditorial
Publié
Date de publication
08/2012
Peer-reviewed
Oui
Volume
31
Numéro
8
Pages
950-952
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Résumé
To report 2 cases of refractory phlyctenular keratoconjunctivitis treated with topical tacrolimus 0.03% ointment (Protopic).
Two white children, aged 5 years and 6 years, respectively, presented with refractory phlyctenular keratoconjunctivitis in 1 eye (left). Both were using corticosteroids and oral erythromycin at presentation with no relief. Examination revealed the presence of catarrhal corneal infiltrates and neovascularization associated with corneal thinning. Topical tacrolimus was added to topical steroids and oral erythromycin twice daily.
Topical tacrolimus 0.03% ointment was applied into the lower fornix twice a day. In both the patients, improvement in symptoms and signs started within a week of therapy. After 3 weeks of treatment, both patients showed complete resolution of corneal infiltrates and neovascularization. Tacrolimus was successfully tapered in both the patients. There were no side effects.
Topical tacrolimus 0.03% ointment may be considered in treating severe refractory phlyctenular conjunctivitis.
Mots-clé
Child, Child, Preschool, Cornea/pathology, Corneal Neovascularization/drug therapy, Female, Humans, Immunosuppressive Agents/administration & dosage, Keratoconjunctivitis/drug therapy, Ointments, Tacrolimus/administration & dosage
Pubmed
Web of science
Création de la notice
01/10/2019 14:40
Dernière modification de la notice
06/10/2019 6:26
Données d'usage